Evidence map›Paper›PMID 39372639›Full record

ReviewIndian journal of nephrology

Impact of Angiotensin Receptor Blockers (ARB) versus Other Antihypertensive Medication on Blood Pressure in Patients on Dialysis: A Meta-Analysis.

Karthika Devi D S, J Jenifer Florence Mary, Reenaa Mohan, Dominika Gavlasova, G Kalaiselvan, E Kathiravan, Jose A Foppiani, V Saravanan, Archana Devi M, Samuel J Lin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Indian journal of nephrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Karthika Devi D SDepartment of Community Medicine, Sri Manakula Vinayagar Medical College and Hospital, Puducherry, India.
J Jenifer Florence MaryDepartment of Community Medicine, Mahatma Gandhi Medical College and Research Institute, SBV (Deemed to be University), Puducherry, India.
Reenaa MohanDepartment of Community Medicine, Sri Manakula Vinayagar Medical College and Hospital, Puducherry, India.
Dominika GavlasovaIKEM, Cardiology Resident, Institute of Clinical and Experimental Medicine, Charles University, Prague, Czechia.
G KalaiselvanDepartment of Community Medicine, AIIMS, Mangalgiri, Andhra Pradesh, India.
E KathiravanDepartment of General Medicine, Indira Gandhi Medical College and Research Institute, Puducherry, India.
Jose A FoppianiBIDMC, Research Fellow, Division of Plastic Surgery, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, Massachusetts, US.
V SaravananDepartment of Community Medicine, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Melmaruvathur, Tamil Nadu, India.
Archana Devi MSri Lalithambigai Medical College and Hospital, Adayalampattu, Maduravoyal, Chennai, Tamil Nadu, India.
Samuel J LinBIDMC, Division of Plastic Surgery, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, Massachusetts, US.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hypertension is an important factor driving mortality among dialysis patients. Angiotensin-II receptor blocker (ARB) has been effective similarly to angiotensin-converting enzymes (ACEs) but with a low incidence of side effects. Methodology: The meta-analysis included all published studies that investigated the effect of ARB on the hypertension in adult dialysis patients (≥18 years). Data extraction was guided by a predetermined checklist. Data sources of the retrieved studies were PubMed, MEDLINE, ScienceDirect, SCOPUS, Cochrane, Web of knowledge, and Google Scholar were systematically searched until February 2023. Using the RevMan 5 software, the mean difference for systolic and diastolic BP (SBP and DBP) and the risk ratio (RR) of the adverse events (AEs) were pooled from the selected studies. The random-effects model was used to compare the difference in the pre-and post-dialysis of the SBP and DBP. Data analyses were performed from December 2022 to February 2023. The primary outcome was the reduction in SBP and DBP in dialysis hypertensive patients who were on anti-hypertensive agents, and the secondary outcome was assessment of AE associated with the drug after dialysis (PROSPERO Registration: CRD42022355369). Results: The initial search yielded 1,679 records, of which 84 studies underwent full-text evaluation, which identified 13 studies and 1,462 patients. The pooled standard MD for losartan with other anti-hypertensive agents, where the pre-dialysis SBP was 0.17 (95% confidence interval [CI]: -0.21-0.55) and the post-dialysis was 0.35 (95% CI: -0.17-1.02); yet, both are statistically non-significant, implies that there was no difference between Losartan and ARB drugs regarding the effect on the SBP. Diastolic BP for predialysis was -0.01 (95% CI: -0.65-0.63) and post-dialysis was 0.03 (95% CI: -0.24-0.30) and statistically non-significant. AEs by the ARB agents were lower compared to other anti-antihypertensive agents (relative risk [RR]: 1.01; 95% CI: 0.59-1.75) and statistically non-significant. Conclusion: This systematic review and meta-analysis of RCT demonstrated that ARB and other anti-hypertensive medications had similar impacts on the treatment of hypertension.

Indexed as

Angiotensin receptor blockerAntihypertensive agentsDiastolic blood pressureHemodialysisLosartanPost-dialysisSystolic blood pressure

Identifiers

PMID39372639
PMCPMC11450773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.